Does Retatrutide Make You Lose Muscle?

Does Retatrutide Make You Lose Muscle?. Does retatrutide make you lose muscle? Yes, some lean mass — but the fat-to-muscle ratio matches other GLP-1s. Here's the Phase 2 data and how to limit it. Key Takeaways Yes — retatrutide causes some muscle (lean mass) loss, but it is not selectively "eating" your muscle. Lean loss is a normal consequence of large, rapid weight loss on any incretin drug. Roughly 25-40% of total weight lost on GLP-1-class drugs is lean mass , and retatrutide's fat-to-lean ratio in trials is comparable to semaglutide and tirzepatide — most of what you lose is fat. Retatrutide produced the largest weight loss of the class — up to ~24.2% at 48 weeks in Phase 2 — so the absolute amount of lean mass lost can be larger simply because total loss is larger. The glucagon (GCGR) arm may be metabolically favorable for energy expenditure, but no trial has shown retatrutide directly builds or fully preserves muscle. Lean-mass loss is largely modifiable: adequate protein intake, progressive resistance training, and avoiding an overly aggressive deficit are the three levers that shift the ratio toward fat. Retatrutide is investigational and for research use only. It is not FDA-approved and nothing here is medical advice. Does Retatrutide Make You Lose Muscle? Yes — retatrutide does cause some muscle loss, but it is not uniquely bad for muscle and it is not selectively targeting lean tissue. When any large caloric deficit drives rapid weight loss, a portion of what comes off is lean mass — muscle, connective tissue, organ mass, and the water they hold — alongside the fat. This happens with diet alone, with bariatric surgery, and with every GLP-1-class compound studied to date. Retatrutide is no exception, and because it produces the largest weight loss in its class, the absolute amount of lean tissue lost can look bigger even when the proportion is normal. The honest framing is this: across incretin weight-loss drugs, roughly 25-40% of total weight lost is lean mass and the remaining 60-75% is fat. In the Phase 2 retatrutide trial ( Jastreboff et al., NEJM 2023 ), body-composition imaging showed fat mass falling substantially more than lean mass, meaning the majority of the weight lost was fat. So the accurate answer is "some muscle, but mostly fat, in a ratio similar to other GLP-1 drugs" — not "retatrutide melts your muscle." What the Phase 2 Body-Composition Data Actually Shows Retatrutide's headline result is potency. In the Phase 2 obesity trial, the 12 mg weekly dose produced a mean weight reduction of about 24.2% at 48 weeks ( Jastreboff et al., NEJM 2023 ) — the largest figure reported for any single agent in the incretin class at the time. That magnitude is exactly why the muscle question matters: the more total weight you lose, the more total lean mass rides along with it. Within that trial, the body-composition substudy showed that fat mass declined proportionally far more than lean mass, and the ratio of fat-to-lean loss was in line with what has been reported for semaglutide and tirzepatide. In other words, potency changed the amount of weight lost, not the quality of the loss. The trial data did not show retatrutide preferentially stripping muscle, nor did it show retatrutide building or fully protecting muscle. It behaves like a very effective fat-loss tool with the same lean-mass caveat every rapid weight-loss intervention carries. How Retatrutide Compares to Semaglutide and Tirzepatide Muscle-loss anxiety usually comes from comparing drugs, so here is the class context. In the STEP-1 semaglutide trial, roughly 39% of the weight lost was lean mass in the DEXA substudy ( Wilding et al., NEJM 2021 ). In the SURMOUNT-1 tirzepatide program, lean mass again made up a minority of total loss with fat mass falling more ( Jastreboff et al., NEJM 2022 ). Retatrutide's reported fat-to-lean ratio sits in the same neighborhood. Compound Receptors Peak trial weight loss Lean mass as share of loss Semaglutide (Ozempic/Wegovy) GLP-1 ~14.9% (STEP-1, 68 wk) ~39% Tirzepatide (Mounjaro/Zepbound) GLP-1 + GIP ~20.9% (SURMOUNT-1, 72 wk) ~25-40% Retatrutide GLP-1 + GIP + GCGR ~24.2% (Phase 2, 48 wk) Comparable class range Best for understanding the takeaway: the percentage of loss that is lean mass is roughly constant across the class; what changes is the total. Because retatrutide loses more total weight faster, a person can lose more absolute muscle even at the same percentage — which is precisely why the muscle-preservation levers below matter more, not less, on the strongest compound. Why Any Rapid Weight Loss Costs Some Muscle Muscle is metabolically expensive to maintain, so when the body is in a sustained energy deficit it will draw on both fat and lean tissue for fuel and will down-regulate the tissue it isn't being asked to use. This is basic energy balance, not a drug-specific effect. The faster and larger the deficit, the more lean mass tends to come along for the ride unless something actively signals the body to keep it. GLP-1-class drugs amplify this in one indirect way: they work largely by suppressing appetite, which can drive protein intake and overall calories very low if a person simply "isn't hungry." Under-eating protein while losing weight quickly is the single biggest driver of avoidable muscle loss. The drug isn't catabolizing muscle directly — the deep, protein-poor deficit it enables is. Does the Glucagon (GCGR) Arm Change Anything? The short answer: possibly favorable for metabolism, but not proven to spare muscle. Retatrutide is a triple agonist that adds glucagon-receptor (GCGR) activity to the GLP-1 and GIP activity that tirzepatide already has. Glucagon-receptor agonism increases energy expenditure and hepatic fat mobilization, which is part of why retatrutide is so effective at reducing fat and liver fat. In theory, a mechanism that pushes energy expenditure and lipolysis could shift body composition toward fat loss. But "in theory" is the operative phrase. No published trial has demonstrated that retatrutide's glucagon arm meaningfully preserves lean mass compared with GLP-1/GIP agents, and none has shown it builds muscle. Ongoing Phase 3 work (tracked on ClinicalTrials.gov ) will give clearer body-composition endpoints. Until then, treat the GCGR "muscle advantage" as a plausible hypothesis, not an established benefit. How to Minimize Muscle Loss (Three Levers) The reason clinicians emphasize lifestyle alongside these drugs is that lean-mass loss is largely modifiable. Three levers do most of the work, and they matter more on a compound as potent as retatrutide. 1. Protein. Adequate protein intake — commonly cited in weight-loss research at roughly 1.2-1.6 g per kg of body weight per day, higher for older or very active individuals — is the strongest dietary signal to retain muscle in a deficit. Because appetite suppression makes it easy to under-eat, protein often has to be prioritized deliberately. 2. Resistance training. Progressive resistance exercise is the mechanical signal that tells the body to keep muscle it would otherwise shed; multiple weight-loss studies show it meaningfully shifts the fat-to-lean ratio. 3. A sane rate of loss. The more aggressive the deficit, the worse the lean-mass ratio — a slower titration and a moderate deficit protect muscle better than crash-style loss. Who Should Worry Most About Muscle Loss Not everyone carries the same risk. Older adults are the highest-priority group: age-related muscle loss (sarcopenia) compounds with weight-loss-related lean loss, and losing muscle in your 60s and 70s has real functional consequences. People starting from lower muscle mass, those eating very little protein, and anyone doing zero resistance training are also at elevated risk of an unfavorable ratio. Conversely, someone with substantial excess fat mass, adequate protein, and a consistent lifting routine will typically lose overwhelmingly fat and preserve most of their muscle — even on a potent triple agonist. Body composition, not the drug alone, determines the outcome. If you're comparing compounds by weight-loss potency, our mazdutide vs tirzepatide vs retatrutide breakdown puts the class in context. Muscle Loss vs. the Other Retatrutide Trade-offs Muscle is one line on a longer ledger. Retatrutide's potency also comes with a dose-dependent side-effect profile — predominantly gastrointestinal — and the deepest appetite suppression of the class, which is the very thing that can drive protein too low. If you're weighing the full picture, our retatrutide side effects breakdown covers the GI and tolerability data, and our guide on whether you can run retatrutide and semaglutide together explains why stacking GLP-1 agents adds side effects without adding benefit. The practical synthesis: retatrutide is the most effective fat-loss compound in the incretin class, it loses lean mass in a normal class-typical ratio, and the amount of muscle you keep is mostly in your control through protein, lifting, and a reasonable rate of loss. "Does it make you lose muscle" is the wrong question; "does it make you lose more fat than muscle , and am I doing the things that keep the ratio favorable" is the right one — and there the answer is encouraging. Frequently Asked Questions Does retatrutide cause muscle loss? Yes, some. A portion of any rapid weight loss is lean mass, and retatrutide is no exception. In Phase 2 trial imaging, fat mass fell substantially more than lean mass, so most of the weight lost was fat — the muscle loss is real but is a minority of total loss and is in the same range as semaglutide and tirzepatide. What percentage of retatrutide weight loss is muscle? Roughly 25-40% of total weight lost on GLP-1-class drugs is lean mass, with the remainder fat. Retatrutide's fat-to-lean ratio in trials is comparable. Because retatrutide loses more total weight (up to ~24.2% in Phase 2), the absolute lean-mass loss can be larger even at a similar percentage. Is retatrutide worse for muscle than tirzepatide or semaglutide? Not proportionally. The share of weight loss that is lean mass is similar across the three. The difference is total magnitude: retatrutide loses more weight, so at the same percentage the absolute amount of muscle can be higher. Per pound lost, it is not uniquely catabolic. Does retatrutide build muscle? No. There is no trial evidence that retatrutide builds muscle or is anabolic. Its glucagon-receptor arm may favor energy expenditure and fat mobilization, but "increases fat loss" is not the same as "builds muscle." Any muscle gain during use would come from training and protein, not the drug. Can you prevent muscle loss on retatrutide? You can't prevent all of it, but you can minimize it. Adequate protein (about 1.2-1.6 g/kg/day), progressive resistance training, and avoiding an overly aggressive deficit are the three levers that shift the ratio toward fat and away from muscle. How much protein should you eat on retatrutide? Weight-loss research commonly targets roughly 1.2-1.6 g of protein per kg of body weight per day to preserve lean mass, with older and more active individuals often at the higher end. The challenge on retatrutide is that strong appetite suppression makes it easy to under-eat, so protein usually has to be prioritized on purpose. Does the glucagon receptor in retatrutide protect muscle? It's a plausible hypothesis, not a proven benefit. Glucagon-receptor agonism raises energy expenditure and mobilizes fat, which could in theory favor fat loss over muscle loss. But no published trial has shown retatrutide preserves lean mass better than GLP-1/GIP agents. Treat it as promising, not established. Who is most at risk of muscle loss on retatrutide? Older adults (where sarcopenia compounds the effect), people starting with lower muscle mass, anyone eating very little protein, and those doing no resistance training. These groups should be the most deliberate about protein and lifting. Will I lose strength on retatrutide? Some strength can follow lean-mass loss if you don't train, but resistance exercise during weight loss preserves both muscle and strength far better than dieting alone. People who keep lifting through the weight loss generally maintain most of their functional strength. Is retatrutide approved for weight loss? No. Retatrutide is investigational and not FDA-approved for any use as of 2026; it is in Phase 3 trials. Material sold as retatrutide is for laboratory research use only and is not intended for human consumption. Nothing here is medical advice. References Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med . 2023;389:514-526. PubMed Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med . 2021;384:989-1002. PubMed Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med . 2022;387:205-216. PubMed U.S. Food & Drug Administration. Drugs@FDA: FDA-Approved Drugs (semaglutide, tirzepatide labeling). accessdata.fda.gov ClinicalTrials.gov. Retatrutide clinical trials registry. clinicaltrials.gov Disclaimer: This article is for educational and research purposes only. Retatrutide is an investigational compound that is not approved by the FDA for human use. Products referenced are intended for laboratory research use only and are not for human consumption. Nothing here is medical advice; consult a qualified healthcare professional for any health decision. PeptideStack page context: visitors can use the header navigation to reach the product catalog, blog, calculators, supplier pages, discount-code pages, contact page, legal policies, privacy policy, terms, and research disclaimer. The site is organized around research peptide education, supplier transparency, product comparison, vendor review content, discount-code tracking, and calculator tools for reconstitution or unit conversion research planning. PeptideStack separates research-use-only peptide information from FDA-approved medication and licensed telehealth pathways. Research peptide pages are informational and are not medical advice, prescription guidance, dosing instructions, treatment recommendations, or instructions for human consumption. Many pages include affiliate disclosures because PeptideStack may earn a commission when visitors click external supplier or telehealth links. That commission does not change the price paid by visitors and does not mean PeptideStack manufactures, sells, distributes, compounds, or ships peptides or medications. Supplier and product pages should be evaluated for third-party testing, batch-specific certificates of analysis, named laboratory verification, transparent pricing, realistic delivery expectations, payment security, refund policies, support quality, and consistent research-use-only labeling. Blog pages connect related guides, comparison articles, FDA approval status explainers, safety context, legality resources, product pages, vendor reviews, and calculator tools so visitors can keep researching without relying on a single supplier claim. Calculator pages are educational tools for laboratory planning and should be cross-checked against professional protocols, institutional requirements, and applicable laws. Legal and disclaimer pages explain the boundaries of PeptideStack content and the responsibility of visitors who evaluate third-party vendors. The rendered interface may add interactive details such as mobile navigation labels, product tabs, share buttons, related article cards, disclosure boxes, call-to-action buttons, vendor selectors, copy-code controls, email-code forms, footer navigation, and status labels. The static HTML fallback includes this context so the same page purpose is understandable before the JavaScript application finishes loading. Visitors should treat PeptideStack as a research and comparison starting point. Final supplier evaluation should include direct review of the external vendor website, current product availability, checkout terms, applicable laws, institutional requirements, and any third-party laboratory documentation available for the exact product or batch being considered. Footer resources repeat important sitewide context: PeptideStack is independent, affiliate-supported, research-focused, and not a pharmacy or manufacturer. Pages may include links to the iOS app, calculators, blog hubs, product hubs, supplier comparisons, support contact, and policy documents. This repeated context is intentionally available in the raw HTML for crawlers that inspect a page before executing the React bundle. Raw HTML also includes page summaries for mobile crawlers using JavaScript rendering, desktop crawlers comparing source to rendered output, accessibility tools, and no-script visitors. The fallback is replaced by the React app in normal browsers but keeps the source document aligned with the visible page topic. This fallback keeps source HTML and rendered HTML closer for crawl diagnostics and SEO audits across crawled pages, routes, reports, and recrawls.